<DOC>
	<DOC>NCT03101722</DOC>
	<brief_summary>To investigate the effects of hearing aid, huperzine A and combination of hearing aid and huperzine A on tinnitus suppression, hearing and cognitive function protection in patients with presbycusis</brief_summary>
	<brief_title>Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD)</brief_title>
	<detailed_description>To continuously recruit about 150 patients with presbycusis and tinnitus and about 400 patients with presbycusis in our hospital of Fudan university.</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Tinnitus</mesh_term>
	<mesh_term>Presbycusis</mesh_term>
	<mesh_term>Huperzine A</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>1. mild to moderate/severe hearing impairment (the pure tone averaged across octave frequencies between 0.25 to 4 kHz of 2679 dB HL) with or without tinnitus; 2. tinnitus existing 3+ months; 3. Han Chinese patients; 4. aged above 60 years. 1. air bone gap average across 0.5, 1 and 2 kHz ≤ 15 dB HL in better hearing ear; 2. first language other than chinese; 3. dependence due to poor physical activity; 4. acute brain trauma and stroke within 2 weeks; 5. psychiatric disorder; 6. vision impairment; 7. normal hearing or hearing impairment above 80 dB HL.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>presbycusis</keyword>
	<keyword>tinnitus</keyword>
	<keyword>cognitive impairment</keyword>
	<keyword>Huperzine A</keyword>
	<keyword>hearing aid</keyword>
	<keyword>age-related hearing impairment</keyword>
</DOC>